Physician profile
Brian D Midkiff
NPI 1184842312
$1,326.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $129 · 2021: $73.45 · 2022: $506 · 2023: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $256.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.15 | 2019-2023 | |
| Exelixis INC. | $234.31 | 2022-2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $144.62 | 2019-2023 | Keytruda |
| Seagen INC. | $137.94 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $73.79 | 2020-2023 | Lynparza |
| Amgen INC. | $49.80 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $29.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.98 | 2021 | |
| Incyte Corporation | $24.98 | 2022 | |
| Cti Biopharma Corp. | $24.97 | 2023 | Vonjo |
| Eisai INC. | $24.00 | 2019 | |
| Celgene Corporation | $22.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Midkiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.